Cargando…
Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom
To assess the risk of autoimmune disease (AD) in 9–25 year-old women within 1 year after the first AS04-HPV-16/18vaccine dose, a retrospective, observational database cohort study was conducted using CPRD GOLD. From CPRD GOLD 4 cohorts (65,000 subjects each) were retrieved: 1 exposed female cohort (...
Autores principales: | Willame, Corinne, Rosillon, Dominique, Zima, Julia, Angelo, Maria-Genalin, Stuurman, Anke L., Vroling, Hilde, Boggon, Rachael, Bunge, Eveline M., Pladevall-Vila, Manel, Baril, Laurence |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137515/ https://www.ncbi.nlm.nih.gov/pubmed/27428517 http://dx.doi.org/10.1080/21645515.2016.1199308 |
Ejemplares similares
-
Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience
por: Angelo, Maria-Genalin, et al.
Publicado: (2014) -
Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme
por: Angelo, Maria-Genalin, et al.
Publicado: (2014) -
Meta‐analysis of the risk of autoimmune thyroiditis, Guillain‐Barré syndrome, and inflammatory bowel disease following vaccination with AS04‐adjuvanted human papillomavirus 16/18 vaccine
por: Rosillon, Dominique, et al.
Publicado: (2020) -
Importance of feasibility assessments before implementing non‐interventional pharmacoepidemiologic studies of vaccines: lessons learned and recommendations for future studies
por: Willame, Corinne, et al.
Publicado: (2016) -
Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12–15 years: Interim analysis of a large community-randomized controlled trial
por: Lehtinen, Matti, et al.
Publicado: (2016)